Rchr
J-GLOBAL ID:202001018331570390   Update date: Feb. 01, 2024

Kobayashi Yuka

Kobayashi Yuka
Research theme for competitive and other funds  (4):
  • 2021 - 2024 ヒト型人工リンパ組織の開発と腫瘍への免疫療法の応用
  • 2018 - 2021 A construction of the functional human type artificial lymphoid tissues toward the the application for antitumor immunotherapy
  • 2007 - 2011 Generation and application of artificial lymphoid tissues
  • 2007 - 2008 Analysis and application of memory T and memory B cells by applying artificial lymph nodes
Papers (11):
  • Yuka Kobayashi, Takeshi Watanabe. Artificial Construction of Immune Tissues/Organoids and Their Application for Immunological Intervention. Current topics in microbiology and immunology. 2020
  • Soki Kashima, Takuya Maeda, Kyoko Masuda, Seiji Nagano, Takamitsu Inoue, Masashi Takeda, Yuka Kono, Takashi Kobayashi, Shigeyoshi Saito, Takahiro Higuchi, et al. Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. iScience. 2020. 23. 4. 100998-100998
  • Makoto Nakamura, Kenichi Arai, Takahito Mimura, Jungo Tagawa, Hirotoshi Yoshida, Koichi Kato, Tadashi Nakaji-Hirabayashi, Yuka Kobayashi, Takeshi Watanabe. Engineering of artificial lymph node. Synthetic Immunology. 2016. 181-200
  • Yuka Kobayashi, Koichi Kato, Makoto Nakamura, Takeshi Watanabe. Synthesis of functional tertiary lymphoid organs. Synthetic Immunology. 2016. 151-169
  • Yuka Kobayashi, Takeshi Watanabe. Gel-Trapped Lymphorganogenic Chemokines Trigger Artificial Tertiary Lymphoid Organs and Mount Adaptive Immune Responses In Vivo. Frontiers in immunology. 2016. 7. 316-316
more...
MISC (1):
  • Junichi Ikenouchi, Miho Matsuda, Yuka Kobayashi, Noriko Iwamoto, Mikio Furuse, Shoichiro Tsukita. Direct repression of the gene expression of claudins/occludin by Snail: Towards the identification of epithelium-specific genes. CELL STRUCTURE AND FUNCTION. 2004. 29. 48-48
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page